Clal Biotechnology Industries Ltd (TA:CBI) — Market Cap & Net Worth
Market Cap & Net Worth: Clal Biotechnology Industries Ltd (CBI)
Clal Biotechnology Industries Ltd (TA:CBI) has a market capitalization of $11.31 Million (ILA4.22 Billion) as of July 22, 2026. Listed on the TA stock exchange, this Israel-based company holds position #26755 globally and #384 in its home market, demonstrating a -1.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clal Biotechnology Industries Ltd's stock price ILA26.90 by its total outstanding shares 156846200 (156.85 Million). See how much does Clal Biotechnology Industries Ltd reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Clal Biotechnology Industries Ltd Market Cap History: 2015 to 2026
Clal Biotechnology Industries Ltd's market capitalization history from 2015 to 2026. Data shows change from $121.28 Million to $11.31 Million (-18.54% CAGR).
Clal Biotechnology Industries Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clal Biotechnology Industries Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.70x
Clal Biotechnology Industries Ltd's market cap is 33.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $121.28 Million | $25.42 Million | -$118.46 Million | 4.77x | N/A |
| 2016 | $89.59 Million | $24.18 Million | -$213.82 Million | 3.70x | N/A |
| 2017 | $125.68 Million | $43.46 Million | -$27.89 Million | 2.89x | N/A |
| 2018 | $101.90 Million | $12.77 Million | -$44.94 Million | 7.98x | N/A |
| 2019 | $49.20 Million | $113.29 Million | -$154.11 Million | 0.43x | N/A |
| 2020 | $73.83 Million | $206.00K | $109.03 Million | 358.41x | 0.68x |
| 2021 | $49.70 Million | $224.00K | -$89.58 Million | 221.89x | N/A |
| 2022 | $26.79 Million | $370.00K | -$61.74 Million | 72.39x | N/A |
| 2023 | $16.65 Million | $104.00K | -$31.05 Million | 160.11x | N/A |
| 2024 | $14.59 Million | $433.00K | -$62.46 Million | 33.70x | N/A |
Competitor Companies of CBI by Market Capitalization
Companies near Clal Biotechnology Industries Ltd in the global market cap rankings as of July 22, 2026.
Key companies related to Clal Biotechnology Industries Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #542 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $482.00 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $675.19 |
| #542 | Argen-X | BR:ARGX | $49.55 Billion | €760.20 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €243.90 |
Clal Biotechnology Industries Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Clal Biotechnology Industries Ltd's market cap moved from $121.28 Million to $ 11.31 Million, with a yearly change of -18.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA11.31 Million | -12.66% |
| 2025 | ILA12.95 Million | -11.24% |
| 2024 | ILA14.59 Million | -12.37% |
| 2023 | ILA16.65 Million | -37.83% |
| 2022 | ILA26.79 Million | -46.11% |
| 2021 | ILA49.70 Million | -32.68% |
| 2020 | ILA73.83 Million | +50.08% |
| 2019 | ILA49.20 Million | -51.72% |
| 2018 | ILA101.90 Million | -18.92% |
| 2017 | ILA125.68 Million | +40.29% |
| 2016 | ILA89.59 Million | -26.13% |
| 2015 | ILA121.28 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 22nd, 2026 the market cap of Clal Biotechnology Industries Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.31 Million USD |
| MoneyControl | $11.31 Million USD |
| MarketWatch | $11.31 Million USD |
| marketcap.company | $11.31 Million USD |
| Reuters | $11.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to i… Read more